Related Experiment Video
Updated: Jul 23, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
Zhen Hui Peh1, Adel Dihoum2, Dana Hutton1
1School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom.
Abstract:
Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Pathophysiology of Heart Failure
Myocarditis III: Medical Management
Heart Failure II: Pathophysiology
Heart Failure VI: Adjunct Therapies

